PL1888031T3 - Preparaty analogu glp-1 - Google Patents

Preparaty analogu glp-1

Info

Publication number
PL1888031T3
PL1888031T3 PL06744133T PL06744133T PL1888031T3 PL 1888031 T3 PL1888031 T3 PL 1888031T3 PL 06744133 T PL06744133 T PL 06744133T PL 06744133 T PL06744133 T PL 06744133T PL 1888031 T3 PL1888031 T3 PL 1888031T3
Authority
PL
Poland
Prior art keywords
glp
analogue formulations
analogue
formulations
Prior art date
Application number
PL06744133T
Other languages
English (en)
Inventor
Fredrik Joabsson
Markus Johnsson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/en
Priority claimed from PCT/GB2005/004752 external-priority patent/WO2006075125A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PL1888031T3 publication Critical patent/PL1888031T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06744133T 2005-06-06 2006-06-06 Preparaty analogu glp-1 PL1888031T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2005/002217 WO2005117830A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
PCT/GB2005/004752 WO2006075125A1 (en) 2005-01-14 2005-12-09 GnRH ANALOGUE FORMULATIONS
PCT/GB2006/002079 WO2006131730A1 (en) 2005-06-06 2006-06-06 Glp-1 analogue formulations
EP06744133A EP1888031B1 (en) 2005-06-06 2006-06-06 Glp-1 analogue formulations

Publications (1)

Publication Number Publication Date
PL1888031T3 true PL1888031T3 (pl) 2013-04-30

Family

ID=36741345

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06744133T PL1888031T3 (pl) 2005-06-06 2006-06-06 Preparaty analogu glp-1

Country Status (9)

Country Link
US (2) US8546326B2 (pl)
EP (1) EP1888031B1 (pl)
JP (1) JP5198261B2 (pl)
CN (1) CN101217940B (pl)
CA (1) CA2609810C (pl)
DK (1) DK1888031T3 (pl)
ES (1) ES2399645T3 (pl)
PL (1) PL1888031T3 (pl)
WO (1) WO2006131730A1 (pl)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2390331C2 (ru) * 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
ES2400034T3 (es) 2005-01-14 2013-04-05 Camurus Ab Formulaciones bioadhesivas tópicas
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
US8871712B2 (en) * 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
CA2595385C (en) * 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
EP3095456A1 (en) 2005-11-04 2016-11-23 Glaxosmithkline LLC Methods for administering hypoglycemic agents
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
MX2009011123A (es) * 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
EP2052716B1 (en) * 2007-10-24 2014-12-31 Camurus AB Controlled release formulations
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
MX352189B (es) * 2008-09-04 2017-11-10 Amylin Pharmaceuticals Llc Formulaciones de liberación sostenida usando portadores no acuosos.
BR122013025625B1 (pt) 2008-10-17 2021-08-03 Sanofi-Aventis Deutschland Gmbh Composição farmacêutica, seu uso e método de preparação da mesma, kit e dispositivo
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
US8795226B2 (en) * 2009-06-25 2014-08-05 Sanofi-Aventis Deutschland Gmbh Cannula assembly for co-delivery of medicaments
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
EP2496249B1 (en) * 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
EP2496664B1 (de) 2009-11-04 2014-10-01 Merck Patent GmbH Verbindungen für ein flüssigkristallines medium und deren verwendung für hochfrequenzbauteile
SI2498801T1 (en) * 2009-11-13 2018-06-29 Sanofi-Aventis Deutschland Gmbh A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
ES2676373T3 (es) 2009-11-13 2018-07-19 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US8314080B2 (en) 2010-04-06 2012-11-20 Kuwait University Method of treating type I diabetes
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2714004T (pt) * 2011-05-25 2024-07-12 Camurus Ab Formulações de peptídeos de libertação controlada
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
DE102011114986A1 (de) * 2011-09-28 2013-03-28 Ethris Gmbh Sprühsystem
US9585959B2 (en) 2011-12-05 2017-03-07 Camurus Ab Robust controlled-release formulations
CA2861261A1 (en) * 2012-01-31 2013-08-08 Santen Pharmaceutical Co., Ltd. Non-aqueous liquid composition
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
WO2013174978A1 (en) * 2012-05-25 2013-11-28 Camurus Ab Somatostatin receptor agonist formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902919B (zh) 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
RU2016132386A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы без глицерина на основе инсулиновых аналогов и/или инсулиновых производных
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160101195A (ko) 2014-01-09 2016-08-24 사노피 인슐린 아스파트의 안정화된 약제학적 제형
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
SG11201608910UA (en) 2014-04-28 2016-11-29 Orphomed Inc Buprenorphine dimer and its use in treatment of gastrointestinal disorders
HRP20211561T8 (hr) 2014-06-12 2022-03-04 Ra Pharmaceuticals, Inc. Modulacija aktivnosti komplementa
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
WO2016123371A1 (en) 2015-01-28 2016-08-04 Ra Pharmaceuticals, Inc. Modulators of complement activity
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3297654B1 (en) 2015-05-22 2021-07-07 The Board of Trustees of the Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
SG11201804721SA (en) 2015-12-16 2018-07-30 Ra Pharmaceuticals Inc Modulators of complement activity
WO2017152014A1 (en) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
MX2018011893A (es) * 2016-03-31 2019-01-10 Sun Pharma Advanced Res Co Ltd Gel viscoelastico de liraglutida adaptado para una administracion semanal o quincenal.
US10954287B2 (en) 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018060213A1 (en) 2016-09-27 2018-04-05 Camurus Ab Formulations containing a somatostatin receptor agonist
RU2757903C2 (ru) 2016-09-15 2021-10-22 Камурус Аб Препараты аналогов простациклина
US11020484B2 (en) 2016-11-21 2021-06-01 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
CN108606957A (zh) * 2016-12-13 2018-10-02 南京星银药业集团有限公司 一种含索马鲁肽的口服缓释制剂及其制备方法
IL307966A (en) 2017-01-03 2023-12-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
EP3842061A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842449A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
BR9206593A (pt) 1991-10-04 1995-11-28 Gs Biochem Ab Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
JP4137179B2 (ja) 1994-03-30 2008-08-20 ジーエス ディベロップメント エービー 生物付着性物質としての脂肪酸エステルの使用
SE518578C2 (sv) * 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
EP0871489A1 (en) 1995-10-12 1998-10-21 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
DK0839525T3 (da) * 1996-10-31 2004-11-29 Takeda Pharmaceutical Præparat med forlænget frigivelse
JP2001524958A (ja) 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ 新規な液晶をベースとする生物接着性薬剤送出系
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
EP1600162A1 (en) 1998-12-22 2005-11-30 Eli Lilly & Company Shelf-stable formulation of glucagon-like peptide-1
US6467987B1 (en) * 1999-03-29 2002-10-22 Honeywell International Inc. Resettable non-explosive actuator
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
WO2003000236A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
JP5562510B2 (ja) * 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
AU2003201998C1 (en) * 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
DE602004017198D1 (de) 2003-08-04 2008-11-27 Camurus Ab Verfahren zum beladen von amphiphilen teilchen mit wirkstoffen
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
MXPA06002941A (es) * 2003-09-19 2006-05-31 Novo Nordisk As Derivados de enlace a albumina de peptidos terapeuticos.
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
EP1682091B1 (en) * 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
JP4966018B2 (ja) 2004-01-23 2012-07-04 カムルス エービー 三元非ラメラ脂質組成物
RU2390331C2 (ru) 2004-06-04 2010-05-27 Камурус Аб Жидкие депо-препараты
WO2006013369A2 (en) 2004-08-04 2006-02-09 Camurus Ab Compositions forming non-lamellar dispersions
CA2594711C (en) 2005-01-14 2012-11-06 Camurus Ab Somatostatin analogue formulations
ES2400034T3 (es) 2005-01-14 2013-04-05 Camurus Ab Formulaciones bioadhesivas tópicas
EP1845942B1 (en) 2005-01-14 2014-04-09 Camurus Ab Gnrh analogue formulations
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
CA2595385C (en) 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
ES2437581T3 (es) 2005-11-17 2014-01-13 Zogenix, Inc. Suministro de formulaciones viscosas por inyección sin aguja
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations

Also Published As

Publication number Publication date
WO2006131730A1 (en) 2006-12-14
JP5198261B2 (ja) 2013-05-15
EP1888031A1 (en) 2008-02-20
CN101217940A (zh) 2008-07-09
US8097239B2 (en) 2012-01-17
US20080124394A1 (en) 2008-05-29
ES2399645T3 (es) 2013-04-02
CA2609810C (en) 2012-05-22
DK1888031T3 (da) 2013-02-18
CA2609810A1 (en) 2006-12-14
US8546326B2 (en) 2013-10-01
EP1888031B1 (en) 2013-01-23
CN101217940B (zh) 2013-03-27
US20080146490A1 (en) 2008-06-19
JP2008542437A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
PL1888031T3 (pl) Preparaty analogu glp-1
GB2424581B (en) Formulations
PL1843746T3 (pl) Formulacje analogów somatostatyny
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
PL1845942T3 (pl) Preparaty analogu GnRH
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
IL186600A0 (en) Novel vaccine formulations
GB0505569D0 (en) Formulations
EP1951693A4 (en) SOLID FORMULATIONS
IL192149A0 (en) Stable s-nitrosothiol formulations
EP1904525A4 (en) GLP-1 PHARMACEUTICAL COMPOSITIONS
GB0523634D0 (en) Solid cleaning formulations
GB0518878D0 (en) Formulations
GB0526322D0 (en) Formulations
GB0522917D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0500912D0 (en) Novel formulations
GB0522828D0 (en) Novel formulations
GB0500913D0 (en) Novel formulations
GB0519090D0 (en) Novel formulations
GB0504106D0 (en) Novel formulations
GB0500917D0 (en) Novel formulations
GB0500915D0 (en) Novel formulations
GB0417226D0 (en) Formulations
IL179208A0 (en) Intereferon formulations